<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7196844\results\search\country\results.xml">
  <result pre="Klinische Pharmakologie und Toxikologie CharitÃ©â€&quot;UniversitÃ¤tsmedizin Berlin Luisenstr. 7, 10117 Berlin," exact="Germany" post="ralf.stahlmann@charite.de ppub: 2020-3epub: 2020-3-3pmc-release: 2020-3-311713213219received: 2020-3-4accepted: 2020-3-13 Background With"/>
  <result pre="standard supportive treatment. The virus SARS-CoV-2, first isolated in Wuhan," exact="China" post="and the pathogen responsible for COVID-19, is spreading rapidly"/>
  <result pre="syndrome (MERS) hit the headlines. MERS was first diagnosed in" exact="Saudi Arabia" post="in 2012 and was fatal in around one in"/>
  <result pre="(figure). Camostat, an inhibitor of this protease, is licensed in" exact="Japan" post="for treatment of chronic pancreatitis (4), but no clinical"/>
  <result pre="such as oseltamivir, darunavir, and umifenovir, which was developed in" exact="Russia" post="for the treatment of influenza (table 1). In view"/>
  <result pre="patients with worsening clinical symptoms received this medication in a" exact="Singapore" post="hospital. Improvement was seen in three patients, but not"/>
  <result pre="of the treatment of a 35-year-old man with COVID-19 in" exact="the USA" post="was published on 5 March 2020 (14). This was"/>
  <result pre="2, 0.5 g on day 3 2900 Lihir Medical Center" exact="Spain" post="(Catalonia)Department of Health, Generalitat de Catalunya July 2020 Hydroxychloroquine"/>
  <result pre="daily for 5 days 30 Shanghai Public Health Clinical Center" exact="China" post="August 2020 Remdesivir Placebo-controlled double-blind trial (1:1 randomization)Participants: Moderately"/>
  <result pre="in 308 patients with mild symptoms. 453 Capital Medical UniversityPeking" exact="China" post="April 2020 Remdesivir Open trial, comparison with standard treatmentParticipants:"/>
  <result pre="2 Ã— 500 mg/day for 2 weeks 400 Tongji Hospital" exact="China" post="July 2020 Thalidomide Placebo-controlled double-blind trialParticipants: Patients with PCR-confirmed"/>
  <result pre="14 days 100 Second Affiliated Hospital of Wenzhou Medical University" exact="China" post="June 2020 rh-ACE2 Pilot study, open designParticipants: Patients with"/>
  <result pre="standard treatment 24 First Affiliated Hospital of Guangzhou Medical University" exact="China" post="April 2020 *1 Altogether, &amp;gt;80 trials have been registered"/>
  <result pre="viral RNA-dependent RNA polymerase, licensed for treatment of influenza in" exact="Japan" post="62 Penciclovir Nucleoside analog, guanosine derivative, inhibits viral DNA"/>
 </snippets>
</snippetsTree>
